Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-314 + SOC
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CKD-314 (Nafabelltan) is a small molecule drug developed by Chong Kun Dang Pharmaceutical. It has been investigated as an intravenous treatment for hospitalized adult patients diagnosed with COVID-19 pneumonia. In clinical trials, the combination "CKD-314 + SOC" refers to the administration of CKD-314 alongside standard of care treatments for COVID-19 pneumonia. The mechanism of action involves inhibition of serine proteases (SP inhibitor), which may modulate inflammatory and coagulation pathways relevant to severe viral infections[10][8][1]. The primary indication in clinical studies has been COVID-19 pneumonia.
- Other names
- Nafabelltan + SOC
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on CKD-314 + SOC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-314 + SOC.